Xstrahl to Showcase Radiant™ Aura at AAD 2024 in San Diego, CA
Radiant Aura is a painless, non-surgical office-based radiation therapy treatment option for patients with non-melanoma skin cancers and keloid scarring
Radiant Aura is the only dual modality surface radiation therapy system that enables you to choose either electronic brachytherapy or SRT based on the needs of your patients.
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Radiant Aura at the American Academy of Dermatology (AAD) 2024 Annual Meeting, March 8-10, 2024, in San Diego, CA. Radiant Aura is a low-dose, X-ray based, dual modality radiation therapy for treating non-melanoma skin cancers (NMSC) and keloid scarring.
On Saturday, March 9, at 2PM, Xstrahl will host a special Radiation Oncologist Forum, led by one of our radiation oncology service providers, Dr. David Greene and Dr. Ankit Agarwal of DermRay. They will provide clinical education to attendees about using radiation therapy to treat NMSC. Stop by Xstrahl booth # 2111 to learn more.
“We’re pleased to showcase Radiant Aura at this year’s AAD meeting. Radiant Aura is a painless non-surgical skin cancer treatment alternative available to support the delivery of office-based radiation therapy for patients with NMSC when surgery is not possible, contraindicated, or simply not preferred due to cosmetic concerns,” said Adrian Treverton, CEO of Xstrahl. He added “The Radiation Oncologist Forum on Saturday will be the perfect opportunity for dermatologists to learn how they can offer radiation therapy. Drs. Greene and Agarwal will be on hand to explain the best way to implement Radiant Aura into dermatology practices across the country.”
“Radiant Aura is an incredible technological innovation in superficial radiation treatment and electronic brachytherapy. The dual modality use, and ease of use of both the hardware and software applications make it my preferred choice for patients and dermatology practices,” said Dr. David Greene, MD, Radiation Oncologist at DermRay.
Radiant Aura is the only dual modality system that offers both non-invasive electronic brachytherapy (eBt) and superficial radiation therapy (SRT) for NMSC and keloid scarring. The device received U.S. Food and Drug Administration (FDA) 510(k) clearance in July 2023. It is commercially available now and available for sale across the US.
Visit Xstrahl at AAD 2024, booth # 2111 at the San Diego Convention Center from March 8-10, 2024.
# # #
For further information, please contact:
Kelly Withers, National Sales Director
Cell: 602-509-4990 or e-mail: kellywithers@xstrahl.com
About Xstrahl
Xstrahl is a medical technology company that designs radiation delivery devices to support clinical teams and cancer researchers. For more than 25 years, Xstrahl has been shaping the development of superficial and orthovoltage radiation therapy and advancing preclinical radiation research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide.
To learn more about Radiant Aura, visit www.radiant-therapy.com
To learn more about all Xstrahl clinical and research systems, visit www.xstrahl.com
